Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Capital Expenditures (2024 - 2025)

Beta Bionics' Capital Expenditures history spans 2 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 239.22% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $5.3 million, up 56.02%, while the annual FY2025 figure was $5.3 million, 56.02% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.9 million at Beta Bionics, down from $3.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.3 million in Q3 2025 and bottomed at -$232000.0 in Q2 2025.